Myriad Genetics' Lead Drug Candidate Accepting Enrollment for a Phase 3 Clinical Trial

27-May-2005

Myriad Genetics' lead drug candidate, FLURIZAN(TM), is currently accepting enrollment for a Phase 3 clinical trial in Alzheimer's disease. This compound is also being studied in a Phase 2b clinical trial for prostate cancer therapy. Myriad has a full pipeline of preclinical drug candidates in development and recently started Phase I human clinical trials for two additional cancer drugs, MPC-6827 and MPC-2130.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance